Invesaro

Stocks Health care RDY

NYSE · Health care

DR Reddys Laboratories Ltd (RDY)

DR Reddys Laboratories Ltd reported revenue of $3.8B in fiscal 2025, up 13.8% from a year earlier. Net income was $663M, a net margin of 17.4%. Operating cash flow minus capital spending left $223M of free cash flow in fiscal 2025. At March 31, 2025 it held $172M in cash.

Price
$12.25
-0.41% on the day · September 25, 2026
52-week range $11.36 to $15.67
Market cap
$10.2B
Revenue (FY2025)
$3.8B
+13.8% year on year
Net margin
17.4%

What DR Reddys Laboratories Ltd does

DR Reddys Laboratories Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RDY.

Revenue and profit by year

Revenue
FY18: $2.2B $2.2B FY18FY19: $2.2B $2.2B FY19FY20: $2.3B $2.3B FY20FY21: $2.6B $2.6B FY21FY22: $2.8B $2.8B FY22FY23: $3B $3B FY23FY24: $3.4B $3.4B FY24FY25: $3.8B $3.8B FY25
Net income
FY18: $151M $151M FY18FY19: $272M $272M FY19FY20: $259M $259M FY20FY21: $236M $236M FY21FY22: $311M $311M FY22FY23: $548M $548M FY23FY24: $668M $668M FY24FY25: $663M $663M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$3.8B$842M$663M$0.79$223M
2024$3.4B$813M$668M$4.01$348M
2023$3B$695M$548M$3.30$578M
2022$2.8B$389M$311M$1.87$177M
2021$2.6B$332M$236M$1.52$355M
2020$2.3B$212M$259M$1.56$332M

Latest SEC filings

What DR Reddys Laboratories Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 22, 2026
    Foreign issuer update 6-K
  2. September 21, 2026
    Foreign issuer update 6-K
  3. September 18, 2026
    Foreign issuer update 6-K
  4. September 14, 2026
    Foreign issuer update 6-K
  5. September 10, 2026
    Foreign issuer update 6-K
  6. September 10, 2026
    Foreign issuer update 6-K
  7. August 26, 2026
    Foreign issuer update 6-K
  8. August 17, 2026
    Foreign issuer update 6-K
  9. August 17, 2026
    Foreign issuer update 6-K
  10. August 13, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 10, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about RDY

What does DR Reddys Laboratories Ltd do?

DR Reddys Laboratories Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RDY.

Is DR Reddys Laboratories Ltd profitable?

Yes. In fiscal 2025 it reported net income of $663M on revenue of $3.8B, a net margin of 17.4%.

How much revenue does DR Reddys Laboratories Ltd make?

In fiscal 2025 DR Reddys Laboratories Ltd reported revenue of $3.8B. That is 13.8% more than a year earlier.

When did DR Reddys Laboratories Ltd last report?

Its newest filing of any kind is the foreign issuer update from September 22, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow RDY

Get an email when DR Reddys Laboratories Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow RDY: get an email when it files

Where the numbers come from

Financial figures are the values DR Reddys Laboratories Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.